Screener
TG Therapeutics
TGTXTG Therapeutics is a fully integrated, commercial-stage biotechnology company dedicated to acquiring, developing, and commercializing novel treatments for B-cell mediated diseases.
Earnings
Next report
Nov 2, 2026 (in a month)Revenue estimate$245.2M
EPS estimate$0.36
Valuation & ratios
Segments
By product
Competitors
By market cap
By revenue growth
By net margin
Profile
TG Therapeutics is a fully integrated, commercial-stage biotechnology company dedicated to acquiring, developing, and commercializing novel treatments for B-cell mediated diseases. The company's primary focus is on autoimmune disorders, particularly multiple sclerosis, where it leverages a clinical development platform to identify and advance potentially best-in-class compounds.
Competitive position
A commercial-stage player in the MS market with a differentiated anti-CD20 monoclonal antibody offering shorter infusion times than some established competitors.
GeographiesUnited States, European Union, Germany
Customer segmentsPatients, Healthcare Providers, Pharmaceutical Distributors
Business modelDirect-to-market, Licensing and Royalties, Research and Development
SuppliersContract manufacturing organizations, Academic centers of excellence, Raw material suppliers, Genome editing technology providers
CustomersSpecialty pharmacies, Hospitals, Infusion centers, International commercialization partners
CountryUnited States of America
Listed1995
Employees264.0
CEOMichael S. Weiss
SectorHealthcare
IndustryBiotechnology
Websitetgtherapeutics.com
FilingsSEC EDGAR
FAQ
- What is TG Therapeutics's market cap?
- TG Therapeutics (TGTX) has a market capitalization of $8.2B and trades on NASDAQ.
- What is TG Therapeutics's revenue and profitability?
- TG Therapeutics generated $799.5M in trailing twelve-month revenue with net income of $441.5M, representing a net margin of 55.2%. Gross margin stands at 82.4%, with free cash flow of -$30.9M. The latest reported period is Q2 2026.
- Who are TG Therapeutics's competitors?
- TG Therapeutics's key competitors include Biogen Inc., Vor Biopharma Inc. Common Stock, Soligenix, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does TG Therapeutics partner with?
- TG Therapeutics's notable partners include Neuraxpharm Pharmaceuticals, S.L., Samsung Biologics, FUJIFILM Diosynth Biotechnologies, and others.
- What subsidiaries does TG Therapeutics have?
- TG Therapeutics's subsidiaries include TG Cell Therapy, Inc..
- Where is TG Therapeutics headquartered?
- TG Therapeutics is headquartered in United States of America and employs approximately 264 people. It has been publicly traded since 1995.
